Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

52 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer

ABSTRACT: This SuperSeries is composed of the following subset Series: GSE25055: Discovery cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer GSE25065: Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer Refer to individual Series

ORGANISM(S): Homo sapiens

SUBMITTER: Christos Hatzis

PROVIDER: E-GEOD-25066 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.

Hatzis Christos C Pusztai Lajos L Valero Vicente V Booser Daniel J DJ Esserman Laura L Lluch Ana A Vidaurre Tatiana T Holmes Frankie F Souchon Eduardo E Wang Hongkun H Martin Miguel M Cotrina José J Gomez Henry H Hubbard Rebekah R Chacón J Ignacio JI Ferrer-Lozano Jaime J Dyer Richard R Buxton Meredith M Gong Yun Y Wu Yun Y Ibrahim Nuhad N Andreopoulou Eleni E Ueno Naoto T NT Hunt Kelly K Yang Wei W Nazario Arlene A DeMichele Angela A O'Shaughnessy Joyce J Hortobagyi Gabriel N GN Symmans W Fraser WF

JAMA 20110501 18

<h4>Context</h4>Prediction of high probability of survival from standard cancer treatments is fundamental for individualized cancer treatment strategies.<h4>Objective</h4>To develop a predictor of response and survival from chemotherapy for newly diagnosed invasive breast cancer.<h4>Design, setting, and patients</h4>Prospective multicenter study conducted from June 2000 to March 2010 at the M. D. Anderson Cancer Center to develop and test genomic predictors for neoadjuvant chemotherapy. Patients ...[more]

PMID: 21558518

Similar Datasets

Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer

Project description:PURPOSE: To develop a predictive test for response and survival following neoadjuvant taxane-anthracycline chemotherapy for HER2-negative invasive breast cancer. METHODS: We developed a microarray-based gene expression test from pre-treatment tumor biopsies (310 patients) to predict favorable outcome based on estrogen receptor (ER) status,pathologic response to chemotherapy, 3-year disease outcomes, and sensitivity to endocrine therapy. Tumors were classified as treatment-sensitive if predicted to have pathologic response (and not resistance) to chemotherapy, or sensitive to endocrine therapy. We tested predictive accuracy, with 95% confidence interval (CI), for pathologic response (PPV, positive predictive value), distant relapse-free survival (DRFS), and absolute risk reduction at median follow-up in 198 other patients. Independence from clinical-pathologic factors was assessed in a multivariate Cox regression analysis based on the likelihood ratio test. Other evaluable, published response predictors (genomic grade index (GGI), intrinsic subtype (PAM50), pCR predictor (DLDA30)) were compared. Neoadjuvant validation cohort of 198 HER2-negative breast cancer cases treated with taxane-anthracycline chemotherapy pre-operatively and endocrine therapy if ER-positive. Response was assessed at the end of neoadjuvant treatment and distant-relapse-free survival was followed for at least 3 years post-surgery.

2011-05-11 | E-GEOD-25065 | biostudies-arrayexpress

Discovery cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer

Project description:PURPOSE: To develop a predictive test for response and survival following neoadjuvant taxane-anthracycline chemotherapy for HER2-negative invasive breast cancer. METHODS: We developed a microarray-based gene expression test from pre-treatment tumor biopsies (310 patients) to predict favorable outcome based on estrogen receptor (ER) status,pathologic response to chemotherapy, 3-year disease outcomes, and sensitivity to endocrine therapy. Tumors were classified as treatment-sensitive if predicted to have pathologic response (and not resistance) to chemotherapy, or sensitive to endocrine therapy. We tested predictive accuracy, with 95% confidence interval (CI), for pathologic response (PPV, positive predictive value), distant relapse-free survival (DRFS), and absolute risk reduction at median follow-up in 198 other patients. Independence from clinical-pathologic factors was assessed in a multivariate Cox regression analysis based on the likelihood ratio test. Other evaluable, published response predictors (genomic grade index (GGI), intrinsic subtype (PAM50), pCR predictor (DLDA30)) were compared. Neoadjuvant study of 310 HER2-negative breast cancer cases treated with taxane-anthracycline chemotherapy pre-operatively and endocrine therapy if ER-positive. Response was assessed at the end of neoadjuvant treatment and distant-relapse-free survival was followed for at least 3 years post-surgery.

2011-05-11 | E-GEOD-25055 | biostudies-arrayexpress

Genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer

Project description:Genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer

| PRJNA134729 | ENA

Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer

2011-05-11 | GSE25065 | GEO

Discovery cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer

2011-05-11 | GSE25055 | GEO

Homo sapiens

Project description:Discovery cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer

| PRJNA142759 | ENA

Homo sapiens

Project description:Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer

| PRJNA142731 | ENA

Transcriptional profiling of human breast tumor samples before and after treatment with chemotherapy with and without bevacizumab.

Project description:Molecular responses in tumors after treatment with antiangiogenic therapy are largely unknown. In this experiment, we have assessed the efficacy of bevacizumab in HER2 negative breast carcinomas treated with a neoadjuvant chemotherapy regimen consisting of sequential anthracycline and taxane. Whole genome gene expression profiles of the tumors before, during and after treatment are compared to shed light on change in transcriptional profile following therapy.

2017-06-30 | E-MTAB-4439 | biostudies-arrayexpress

Changes in miRNA expression through the course of neaodjuvant Avastin in breast cancer

Project description:Molecular responses in breast cancer tumors after treatment with antiangiogenic therapy are largely unknown. In this experiment, we have assessed the efficacy of bevacizumab in HER2 negative breast carcinomas treated with a neoadjuvant chemotherapy regimen consisting of sequential anthracycline and taxane. miRNA expression profiles of the tumors before, during and after treatment are compared to shed light on changes in miRNA profile following therapy.

2020-01-01 | E-MTAB-7634 | biostudies-arrayexpress

Detection and quantification of ANXA6 in blood-EVs from breast cancer patients undergoing neoadjuvant chemotherapy

Project description:Annexin 6 (ANXA6) is a calcium-binding, membrane-associated protein involved in membrane trafficking and cell signalling. Furthermore, ANXA6 has been recently associated to cancer progression and metastasis. The goal of the project was to assess the content of ANXA6 in EVs isolated from the plasma of 6 breast cancer patients undergoing anthracycline/taxane-based neoadjuvant chemotherapy.

2019-01-02 | PXD010292 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data